The Pakistani government will extend dedicated support to domestic pharmaceutical companies to accelerate biotech research, a move aimed at boosting innovation in biologics, vaccines, and advanced therapies. This initiative strengthens the country’s commitment to building a self-reliant healthcare system.

Under this effort, pharma firms will receive research grants, regulatory assistance, and access to shared biotech facilities. A focus on public-private partnerships will enable collaborations with universities and startups, creating an ecosystem conducive to cutting-edge scientific breakthroughs.

Government incentives include tax breaks, fast-track approval for biotech products, and investment in local laboratory infrastructure. These measures intend to reduce development costs and speed up the time-to-market for innovative healthcare solutions.

By promoting biotech capacity, Pakistan aims to lessen its dependence on imported biologics and vaccines, improving health security and making treatments more affordable. The strategy also targets economic growth, offering new opportunities in high-value biotech sectors and strengthening export potential.

The government’s commitment signals a transformative shift for the local pharma industry, positioning it to contribute significantly to global biotech innovation while addressing domestic healthcare needs.